Pillar 1
Multi-Omic Discovery
Genomic, proteomic, and lipidomic profiling for disease-specific molecular signatures across neurodegenerative and cardiometabolic conditions.
Scientific Pillars & Consortium Structure
Integrated infrastructure designed for end-to-end translational impact
COPATHOS coordinates discovery, biomarker development, neuropathological validation, and regulatory deployment within a single framework for overlapping neurological disease states — including coexisting Alzheimer's, Parkinson's, frontotemporal dementias, and cerebrovascular and cardiometabolic disease.
Four Scientific Pillars
Pillar 2
Fluid Biomarker Innovation
Next-generation blood-based and CSF biomarker panels for differential diagnosis of coexisting pathologies.
Pillar 3
Neuropathological Validation
Biomarker performance verified against autopsy-confirmed diagnoses to establish neuropathological ground truth.
Pillar 4
Translational Deployment
Assay standardization, regulatory strategy, and clinical implementation for real-world diagnostic use.
Leadership Integration
The translational pipeline: end-to-end coverage
- CC
Stage 1
Gene Discovery & Multi-Omic Profiling
Carlos Cruchaga, PhDNeurogenomics & Multi-Omic Integration
- TK
- RR
Stage 3
Neuropathological Ground Truth & Clinical Trial Validation
Robert A. Rissman, PhDBiomarker Validation & Translational Pathology
- TV
Stage 4
Assay Standardization, Regulatory Strategy & Deployment
Timothy E. Van Meter, PhDDiagnostic Technology & Consortium Operations
Together, COPATHOS leadership covers the complete translational arc from molecular target identification to clinical diagnostic deployment.
Organizational Structure
Steering Committee
Four Co-Directors providing strategic leadership.
Scientific Advisory Board
External domain experts and NIH advisors.
Core Facilities
Biomarker Lab · Biorepository · Neurogenomics Center · Diagnostic Development.
Data Coordination Center
Centralized data management, harmonization, and analytics.
Clinical Sites Network
Multi-site cohorts for recruitment, sample collection, and validation.
Integrated infrastructure designed for end-to-end translational impact
Consortium Programs
Where leadership expertise is applied
Clinical Biomarker Integration & Trial-Readiness Platform
Robert A. Rissman, PhD
Translates biomarker discoveries from genomics, proteomics, and fluid-based assays into diagnostic algorithms, trial-enrichment strategies, and precision-treatment frameworks.
Systems Biology & Multi-Omics Architecture Program
Carlos Cruchaga, PhD
Integrates genetic, proteomic, lipidomic, and transcriptomic signals into mechanistically grounded diagnostic panels and therapeutic-target maps.
Fluid Biomarker Development & Clinical Implementation Program
Thomas K. Karikari, PhD
Advances next-generation assays that distinguish overlapping disease processes and support risk stratification and treatment optimization.
Partner with us to advance the science of differential diagnosis.
Contact the consortium